|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival显示文摘BACKGROUND: In a multidisciplinary conference patients with advanced non-resectable hepatocellular carcinoma (HCC) were stratified according to their clinical status and tumor extent to different regional modalities or to best supportive care. The present study evaluated all patients who were stratified to repeated transarterial chemoembolization (TACE) from 1999 until 2003 in terms of tumor response, toxicity, and survival. A moderate embolizing approach was chosen using a combination of degradable starch microspheres (DSM) and iodized oil (Lipiodol) in order to combine anti-tumoral efficiency and low toxicity. METHODS: Fourty-seven patients were followed up prospectively. TACE treatment consisted of cisplatin (50 mg/m2), doxorubicin (50 mg/m2), 450-900 mg DSM, and 5-30 ml Lipiodol. DSM and Lipiodol were administered according to tumor vascularization. Patient characteristics,toxicity, and complications were outlined. In multivariate regression analyses of pre-treatment variables from a prospective database, predictors for tumor response and survival after TACE were determined. RESULTS: 112 TACE courses were performed (2.4±1.5 courses per patient). Mean maximum tumor size was 75 (± 43) mm, in 68% there was bilobar disease. Best response to TACE treatment was: progressive disease (PD) 9%, stable disease (SD) 55%, partial remission (PR) 36%, and complete remission (CR) 0%. Multivariate regression analyses identified tumor size ≤75 mm, tumor number ≤5, and tumor hypervascularization as predictors for PR. The overall 1-, 2-, and 3-year-survival rates were 75%, 59%, and 41%, respectively, and the median survival was 26 months. Low α-fetoprotein levels (<400 ng/ml) (Odds ratio=3.3) and PR as best response to TACE (Odds ratio=6.7) were significantly associated with long term survival (>30 months, R2=36%). Grade 3 toxicity occurred in 7.1% (n=8), and grade 4 toxicity in 3.6% (n=4) of all courses in terms of reversible leukopenia and thrombocytopenia. The incidence of major complications was 5.4% (n=6). All complications were managed conservatively. The mortality within 6 weeks after TACE was 2.1% (one patient). CONCLUSIONS: DSM and Lipiodol were combined successfully in the palliative TACE treatment of advanced HCC resulting in high rates of tumor response and survival at limited toxicity. Favourable tumor response was associated with tumor extent and vascularization. TACE using DSM and Lipiodol can be considered a suitable palliative measure in patients who might not tolerate long acting embolizing agents. | Timm D Kirchhoff Joerg S Bleck Arne Dettmer Ajay Chavan Herbert Rosenthal Sonja Merkesdal Bernd Frericks Lars Zender Nisar P Malek Tim F Greten Stefan Kubicka Michael P Manns Michael Galanski | 2007 | Hepatobiliary & Pancreatic Diseases International2007，6，3： | 15 |
| 2 | Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma显示文摘瞄准:为病人评估经皮的乙醇注射(PEI ) 的治疗效果与先进, non-resectable HCC 与 transarterial chemoembolisation 的联合相比(不作声) 并且重复单个会议的 PEI,独自重复了单个会议的 PEI,重复不作声独自一个,或最好的支持的照顾。方法:在学习时期期间接受了 PEI 治疗的所有病人根据物理地位和肿瘤程度被包括并且成层到下列治疗形式之一:联合不作声并且重复单个会议的 PEI,独自重复了单个会议的 PEI,重复不作声独自一个,或最好的支持的照顾。包括Okuda分类,门静脉血栓的存在,腹水的存在,肿瘤的数字,最大的肿瘤直径,和假胆硷酯酶( CHE )的临床的参数的预示的价值,以及孩子呸上演, alpha-fetoprotein (法新社),发烧,复杂并发症的发生在这些组之间被估计并且比较。幸存用 Kaplan-Meier 被决定,多,变量回归分析。结果:所有病人的 1 年、 3 年的幸存是 73% 和 47% 。在亚群分析,联合不作声, PEI (1 ) 与更长的幸存被联系(1- , 3- , 5 年的幸存:90% , 52% ,和 43%) 与 PEI 治疗相比独自一个(2 )(1- , 3- , 5 年的幸存:65% , 50% ,和 37%) 。(3 ) 在起始的层化以后的第二等的 PEI 产出可比较的结果不作声(1- , 3- , 5 年的幸存:91% , 40% ,和 30%) 当在到最好的支持的照顾(4 ) 的层化以后的 PEI 与减少的幸存被联系时(1- , 3- , 5 年的幸存:50% , 23% , 12%) 。除了选择治疗形式,为更好的幸存的预言者是肿瘤数字(n <
5 ) ,肿瘤尺寸(<
5 厘米) ,在 PEI 前的没有腹水,和在 PEI 以后的稳定的假胆硷酯酶(P <
0.05 ) 。在在 PEI 以后的 2 wk 以内的死亡是 2.8%(n = 3 ) 。有 24 (8.9%) 主修在包括部分肝梗塞,焦点的肝坏死,和肝脓肿的 PEI 以后的复杂并发症。所有复杂并发症能非通过手术被管理。结论:重复单个会议的 PEI 在有以可接受、可管理的复杂并发症率的先进 HCC 的病人是有效的。病人们成层到联合不作声, PEI 能比那些独自成层到重复 PEI 期望更长的幸存。而且,有在好临床的地位的大或多重的肿瘤的病人可以也从联合获利不作声并且为第二等的 PEI 的再考虑。 | Arne Dettmer Timm D Kirchhoff Michael Gebel Lars Zender Nisar P Malek Bernhard Panning Ajay Chavan Herbert Rosenthal Stefan Kubicka Susanne Krusche Sonja Merkesdal Michael Galanski Michael P Manns Joerg S Bleck | 2006 | World Journal of Gastroenterology2006，12，23： | 14 |
| 3 | Transcutaneous perianal sonography:A sensitive method for the detection of perianal inflammatory lesions in Crohn's disease显示文摘AIM: Pelvic magnetic resonance imaging (MRI) and endoanalultrasound which are established imaging methods forperianal inflammatory lesions in patients with Crohn'sdisease require expensive specialized equipments andexpertise. We investigated the feasibility and sensitivity oftranscutaneous perianal ultrasound (PAUS) using regularultrasound probes in the imaging of perianal inflammatorylesions. The sonographic findings were correlated to pelvicMRI-scans.METHODS: We performed PAUS in 25 patients with Crohn'sdisease and clinical signs of perianal inflammatory disease.VCChin a median of 10 d (range 0-75) these patients underwentMRI of the pelvis. Regular convex and linear high resolutionprobes were used for PAUS. The sonographic findings werecorrelated to the MRI findings by blinded investigators.RESULTS: The sonographic investigations were welltolerated by all patients. Fistulae typically presented ashypoechoic tracks. Twenty-nine fistulae were detected in22 patients. Abscesses were detected in 7 patients andpresented as hypo- or anechoic formations. Twenty-six of29 fistulae and 6 of 7 abscesses could be confirmed byMRI. Kappa statistics showed an excellent agreement(kappa>0.83) between the two imaging methods.CONCLUSION: PAUS is a simple, painless, feasible, real-time method that can be performed without specific patientpreparation which is comparable in its sensitivity to pelvicMRI in the detection of perianal fistulae and/or abscesses.PAUS can especially be recommended as a screening toolin acute perianal disorders such as perianal abscess andfor follow-up studies of perianal inflammatory disease. | Jochen Wedemeyer Timm Kirchhoff Gernot Sellge Oliver Bachmann Joachim Lotz Michael Galanski Michael P.Manns Michael J.Gebel Jrg S.Bleck | 2004 | World Journal of Gastroenterology2004，10，19： | 8 |
| 4 | Sequence diversity of hepatitis C virus: Implications for immune control and therapy显示文摘With approximately 3% of the world’s population (170 million people) infected with the hepatitis C virus (HCV), the WHO has declared HCV a global health problem. Upon acute infection about 50%-80% of subjects develop chronic hepatitis with viral persistence being at risk to develop liver cirrhosis and hepatocellular carcinoma. One characteristic of HCV is its enormous sequence diversity, which represents a significant hurdle to the development of both effective vaccines as well as to novel therapeutic interventions. Due to a polymerase that lacks a proofreading function HCV presents with a high rate of evolution, which enables rapid adaptation to a new environment including an activated immune system upon acute infection. Similarly, novel drugs designed to specifically inhibit viral proteins will face the potential problem of rapid selection of drug resistance mutations. This review focuses on the sequence diversity of HCV, the driving forces of evolution and the impact on immune control and treatment response. An important feature of any therapeutic or prophylactic intervention will be an efficient attack of a structurally or functionally important region in the viral protein. The understanding of the driving forces, but also the limits of viral evolution, will be fundamental for the design of novel therapies. | Joerg Timm Michael Roggendorf | 2007 | World Journal of Gastroenterology2007，13，36： | 5 |
| 5 | Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver显示文摘AIM: In nonresectable cholangiocellular carcinoma (CCC)therapeutic options are limited. Recently, systemic chemotherapy has shown response rates of up to 30%.Additional regional therapy of the arterially hyper vascularized hepatic tumors might represent a rational approach in an attempt to further improve response and palliation. Hence, a protocol combining transarterial chemoembolization and systemic chemotherapy was applied in patients with CCC limited to the liver.METHODS: Eight patients (6 women, 2 men, mean age 62 years) with nonresectable CCC received systemic chemotherapy (gemcitabine 1 000 mg/m2) and additional transarterial chemoembolization procedures (50 mg/m2cisplatin, 50 mg/m2 doxorubicin, up to 600 mg degradable starch microspheres). Clinical follow-up of patients, tumor markers, CT and ultrasound were performed to evaluate maximum response and toxicity.RESULTS: Both systemic and regional therapies were tolerated well; no severe toxicity (WHO Ⅲ/Ⅳ) was encountered. Nausea and fever were the most commonly observed side effects. A progressive rarefication of the intrahepatic arteries limited the maximum number of chemoembolization procedures in 4 patients. A median of 2 chemoembolization cycles (range, 1-3) and a median of 6.5 gemcitabine cycles (range, 4-11) were administered.Complete responses were not achieved. As maximum response, partial responses were achieved in 3 cases,stable diseases in 5 cases. Two patients died from progressive disease after 9 and 10 mo. Six patients are still alive. The current median survival is 12 mo (range, 9-18); the median time to tumor progression is 7 mo (range, 3-18). Seven patients suffered from tumor-related symptoms prior to therapy, 3 of these experienced a treatment-related clinical relief. In one patient the tumor became resectable under therapy and was successfully removed after 10 mo.CONCLUSION: The present results indicate that a combination of systemic gemcitabine therapy and repeated regional chemoembolizations is well tolerated and may enhance the effect of palliation in a selected group of patients with intrahepatic nonresectable CCC. | Timm Kirchhoff Lars Zender Sonja Merkesdal Bernd Frericks Nisar Malek Joerg Bleck Stefan Kubicka Stefan Baus Ajay Chavan Michael P.Manns Michael Galanski | 2005 | World Journal of Gastroenterology2005，11，8： | 3 |
| 6 | Induction of Apoptosis in Malignant B Cells by Phenylbutyrate or Phenylacetate in Combination with Chemotherapeutic Agents显示文摘 | THOMAS E WITZIG MICHAEL TIMM | 2000 | Clinical Cancer Res2000，6，： | 1 |
| 7 | Contrast enhanced gray-scale sonography in assessment of joint vascularity in rheumatoid arthritis: results from the IACUS study group显示文摘 | Andrea Klauser Johannes Demharter Armanda Marchi Delia Sureda Antonio Barile Carlo Masciocchi Carlo Faletti Michael Schirmer Timm Kleffel Klaus Bohndorf | 2005 | European Radiology2005，，12： | 1 |
| 8 | Contrast enhanced gray-scale sonography in assessment of joint vascularity in rheumatoid arthritis: results from the IACUS study group显示文摘 | Andrea Klauser Johannes Demharter Armanda Marchi Delia Sureda Antonio Barile Carlo Masciocchi Carlo Faletti Michael Schirmer Timm Kleffel Klaus Bohndorf | 2005 | European Radiology2005，，12： | 1 |
| 9 | Phase synchronization between LFP and spiking activityin motor cortex during movement preparation显示文摘 | Denker Michael Boux Sebastien Timme Marc | 2007 | Neu-rocomputing2007，70，6： | 1 |
| 10 | Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology显示文摘 | Holger Amthauer Timm Denecke Beate Rau Bert Hildebrandt Michael Hünerbein Juri Ruf Ulrike Schneider Matthias Gutberlet Peter M. Schlag Roland Felix Peter Wust | 2004 | European Journal of Nuclear Medicine and Molecular Imaging2004，，6： | 1 |
| 11 | Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis显示文摘 | Hans D. Theiss Markus Vallaster Christoph Rischpler Lisa Krieg Marc-Michael Zaruba Stefan Brunner Yordan Vanchev Rebekka Fischer Michael Gr?bner Bruno Huber Timm Wollenweber Gerald Assmann Josef Mueller-Hoecker Markus Hacker Wolfgang-M. Franz | 2011 | Stem Cell Research2011，，3： | 1 |
| 12 | Hepatic artery embolization for treatment of patients with hereditary hemorrhagic telangiectasia and symptomatic hepatic vascular malformations显示文摘 | Ajay Chavan Martin Caselitz Karl-Friedrich Gratz Joachim Lotz Timm Kirchhoff Plinio Piso Siegfried Wagner Michael Manns Michael Galanski | 2004 | European Radiology2004，，11： | 1 |
| 13 | Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology显示文摘 | Holger Amthauer Timm Denecke Beate Rau Bert Hildebrandt Michael Hünerbein Juri Ruf Ulrike Schneider Matthias Gutberlet Peter M. Schlag Roland Felix Peter Wust | 2004 | European Journal of Nuclear Medicine and Molecular Imaging2004，，： | 1 |
| 14 | The cross species prediction of bacterial promoters using a support vector machine显示文摘 | Michael Towsey Peter Timms James Hogan Sarah A Mathews | 2008 | Computational Biology and Chemistry2008，32，5： | 1 |
| 15 | Contrast enhanced gray-scale sonography in assessment of joint vascularity in rheumatoid arthritis: results from the IACUS study group显示文摘 | Andrea Klauser Johannes Demharter Armanda Marchi Delia Sureda Antonio Barile Carlo Masciocchi Carlo Faletti Michael Schirmer Timm Kleffel Klaus Bohndorf | 2005 | European Radiology2005，，12： | 1 |
| 16 | Plasma Levels of Matrix Metalloproteinase-2 (MMP-2) and Tissue Inhibitors of Metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as Noninvasive Markers of Liver Disease in Chronic Hepatitis C Comparison Using ROC Analysis显示文摘 | Kevin Michael Walsh Peter Timms Stewart Campbell Ronald Norman Maciver Macsween Allan John Morris | 1999 | Digestive Diseases and Sciences1999，，3： | 1 |
| 17 | Plasma Levels of Matrix Metalloproteinase-2 (MMP-2) and Tissue Inhibitors of Metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as Noninvasive Markers of Liver Disease in Chronic Hepatitis C Comparison Using ROC Analysis显示文摘 | Kevin Michael Walsh Peter Timms Stewart Campbell Ronald Norman Maciver Macsween Allan John Morris | 1999 | Digestive Diseases and Sciences1999，，3： | 1 |
| 18 | CELLULAR FUNCTION OF PHOSPHOINOSITIDE 3-KINASES: Implications for Development, Immunity, Homeostasis, and Cancer显示文摘 | Roy Katso Klaus Okkenhaug Khatereh Ahmadi Sarah White John Timms Michael D. Waterfield | 2001 | Annual Review of Cell and Developmental Biology2001，，： | 1 |
| 19 | Plasma Levels of Matrix Metalloproteinase-2 (MMP-2) and Tissue Inhibitors of Metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as Noninvasive Markers of Liver Disease in Chronic Hepatitis C Comparison Using ROC Analysis显示文摘 | Kevin Michael Walsh Peter Timms Stewart Campbell Ronald Norman Maciver Macsween Allan John Morris | 1999 | Digestive Diseases and Sciences1999，，3： | 1 |
| 20 | Long-term complications of the transmeatal approach (Open Transcanal) in cochlear implants: A follow-up study显示文摘Objective: Multiple alternative approaches of cochlear implant surgery have been described, such as the suprameatal approach, transcanal approach, transmeatal approach and middle cranial fossa approach.Transmeatal(open trnascanal) approach has not been adapted since first described in the clinical field.we aimed to assess the long-term complications of the transmeatal approach in a series of 131 patients at our center between 2004 and 2008.Methods: This study was a retrospective case series of all patients who underwent cochlear implants with the transmeatal(open transcanal) approach from May 2004 to December 2008 at King Faisal Specialist and Research Hospital(Riyadh, Saudi Arabia), which were conducted by the same surgeon.Results: Complications were observed often with various combinations-recurrent otitis externa, posterior tympanic membrane perforation, electrode extrusion, cholesteatoma, and chronic mastoiditis. The overall long-term complication rate was 16%(21/131). The gap between the implantation and the diagnosis of a complication ranged from <1 year to 11 years. Major complications were as follows:cholesteatoma in 5(3.8%) patients, extrusion of the electrode in 5(3.8%) patients, and tympanic membrane perforation or deep retractions in 5(3.8%) patients. Minor complications were as follows: recurrent mastoiditis with/without concomitant temporary facial nerve palsy in 4(3%) patients, recurrent otitis externa infections in 7(5%) patients, and weakness of the posterior canal wall in 1 patient.Conclusion: The transmeatal approach posed an high rate of complications on long-term follow-up such as cholestetoma formation, extrusion of electrode or perielectrode reaction formation to tympanic membrane and external auditory canal. | Hesham Saleh Almofada Nasser KAlmutairi Michael Steven Timms | 2023 | Journal of Otology2023，18，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员